Table 2.
Symptom duration and first line treatment characteristics of midline and hemispheric pediatric high-grade gliomas (pHGGs) overall and differentiated by sex during the period 2003–2017 in the Netherlands
| Midline |
Hemispheric |
|||||||
|---|---|---|---|---|---|---|---|---|
| Overall |
Boys |
Girls |
Pa | Overall |
Boys |
Girls |
Pa | |
| (N=217) | (N=102) | (N=115) | (N=55) | (N=36) | (N=19) | |||
| Symptom duration, days (IQR) | 21 (14–61) | 21 (14–30) | 21 (14–61) | 0.62 | 21 (7–30) | 14 (4–46) | 21 (14–30) | 0.6 |
| Care setting | ||||||||
| Pediatric oncology | 213 (98.2%) | 100 (98.0%) | 113 (98.3%) | 1 | 50 (90.9%) | 33 (91.7%) | 17 (89.5%) | 1 |
| Adult | 4 (1.8%) | 2 (2.0%) | 2 (1.7%) | 5 (9.1%) | 3 (8.3%) | 2 (10.5%) | ||
| No Therapy | 21 (9.7%) | 12 (11.7%) | 9 (7.9%) | 3 (5.5%) | 3 (8.3%) | 0 (0%) | ||
| Died quickly after diagnosis | 2 (0.9%) | 1 (1.0%) | 1 (0.9%) | 0.4 | 1 (1.8%) | 1 (2.8%) | 0 (0%) | 0.7 |
| High tumor load/Extensive disease | 7 (3.2%) | 5 (4.9%) | 2 (1.7%) | 2 (3.6%) | 2 (5.6%) | 0 (0%) | ||
| Comorbidity | 1 (0.5%) | 1 (1.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Functional status | 2 (0.9%) | 1 (1.0%) | 1 (0.9%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Wish/Refusal patient or family | 7 (3.2%) | 2 (2.0%) | 5 (4.3%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Not defined | 2 (0.9%) | 2 (2.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Neurosurgery | ||||||||
| GTR | 7 (3.2%) | 3 (2.9%) | 4 (3.5%) | 0.94 | 25 (45.5%) | 13 (36.1%) | 12 (63.2%) | 0.02 |
| None | 128 (59.0%) | 62 (60.8%) | 66 (57.4%) | 1 (1.8%) | 1 (2.8%) | 0 (0%) | ||
| Biopsy | 40 (18.4%) | 19 (18.6%) | 21 (18.3%) | 11 (20.0%) | 11 (30.6%) | 0 (0%) | ||
| STR | 42 (19.4%) | 18 (17.6%) | 24 (20.9%) | 18 (32.7%) | 11 (30.6%) | 7 (36.8%) | ||
| Radiotherapy | ||||||||
| No | 47 (21.7%) | 25 (24.5%) | 22 (19.1%) | 0.43 | 13 (23.6%) | 9 (25.0%) | 4 (21.1%) | 1 |
| Yes | 170 (78.3%) | 77 (75.5%) | 93 (80.9%) | 42 (76.4%) | 27 (75.0%) | 15 (78.9%) | ||
| Radiotherapy, median total dose in Gy (IQR) | 45.0 (39.0–54.0) | 54.0 (39.0–54.0) | 44.8 (39.0–54.0) | 0.09 | 59.4 (54.0–59.9) | 59.4 (54.0–59.6) | 59.4 (59.4–59.9) | 0.29 |
| Radiotherapy, median fractions (IQR) | 17.0 13.0–30.0) | 28.0 (13.0–30.0) | 16.0 (13.0–30.0) | 0.26 | 30.0 (30.0–33.0) | 30.0 (30.0–33.0) | 30.0 (30.0–33.0) | 0.88 |
| Systemic therapy | ||||||||
| None | 148 (68.2%) | 69 (67.6%) | 79 (68.7%) | 1 | 16 (29.1%) | 11 (30.6%) | 5 (26.3%) | 0.85 |
| Chemo | 63 (29.0%) | 30 (29.4%) | 33 (28.7%) | 38 (69.1%) | 24 (66.7%) | 14 (73.7%) | ||
| Chemo + Target | 6 (2.8%) | 3 (2.9%) | 3 (2.6%) | 1 (1.8%) | 1 (2.8%) | 0 (0%) | ||
| Temozolomide | ||||||||
| No | 174 (80.2%) | 82 (80.4%) | 92 (80.0%) | 1 | 21 (38.2%) | 14 (38.9%) | 7 (36.8%) | 1 |
| Yes | 43 (19.8%) | 20 (19.6%) | 23 (20.0%) | 34 (61.8%) | 22 (61.1%) | 12 (63.2%) | ||
| Dexamethasone | ||||||||
| No | 81 (37.3%) | 46 (45.1%) | 35 (30.4%) | 0.04 | 25 (45.5%) | 17 (47.2%) | 8 (42.1%) | 0.94 |
| Yes | 136 (62.7%) | 56 (54.9%) | 80 (69.6%) | 30 (54.5%) | 19 (52.8%) | 11 (57.9%) | ||
IQR, interquartile range; Gy, gray.
a
Pearson’s Χ2 test or Fisher’s Exact test (when N ≤ 5 in one or more categories). For continuous variables the Wilcoxon rank test was used.